Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

被引:86
|
作者
Zivadinov, R. [1 ,2 ]
Bergsland, N. [1 ]
Dolezal, O. [3 ,4 ]
Hussein, S. [1 ]
Seidl, Z. [5 ]
Dwyer, M. G. [1 ]
Vaneckova, M. [5 ]
Krasensky, J. [5 ]
Potts, J. A. [7 ]
Kalincik, T. [3 ,4 ,6 ]
Havrdova, E. [3 ,4 ]
Horakova, D. [3 ,4 ]
机构
[1] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Buffalo, NY 14203 USA
[2] SUNY Buffalo, Jacobs Neurol Inst, Buffalo, NY 14203 USA
[3] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Radiol, Prague, Czech Republic
[6] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Melbourne, Vic 3010, Australia
[7] Biogen Idec Inc, Weston, MA USA
关键词
GRAY-MATTER ATROPHY; CLINICALLY ISOLATED SYNDROMES; VOXEL-BASED ANALYSIS; MULTIPLE-SCLEROSIS; BRAIN ATROPHY; GREY-MATTER; INTERFERON BETA-1A; MODERN VIEWS; FOLLOW-UP; IMAGES;
D O I
10.3174/ajnr.A3503
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.
引用
收藏
页码:1931 / 1939
页数:9
相关论文
共 50 条
  • [41] A phase II trial of neuroprotection with riluzole in early relapsing-remitting MS
    Waubant, E.
    Maghzi, A. H.
    Revirajan, N.
    Spain, R.
    Julian, L.
    Mowry, E.
    Liu, S.
    Jin, C.
    Green, A. J.
    McCulloch, C. E.
    Pelletier, D.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 560 - 560
  • [42] Cognitive evolution over 5 years can be predicted by magnetic resonance imaging in early relapsing-remitting multiple sclerosis
    Deloire, Mathilde
    Brochet, Bruno
    Bonnet, Melissa
    Salort-Campana, Emmanuelle
    Ouallet, Jean-Christophe
    Hamel, Delphine
    Jove, Jeremy
    Dousset, Vincent
    MULTIPLE SCLEROSIS, 2008, 14 : S255 - S255
  • [43] Thalamus volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients
    Rojas, Juan I.
    Murphy, Georgina
    Sanchez, Francisco
    Patrucco, Liliana
    Fernandez, Maria C.
    Miguez, Jimena
    Funes, Jorge
    Golimstok, Angel
    Cristiano, Edgardo
    NEURORADIOLOGY JOURNAL, 2018, 31 (04): : 350 - 355
  • [44] Defining brain volume cut-offs to predict disability progression in MS: an analysis of a large cohort of relapsing-remitting MS patients
    Sormani, M. P.
    Kappos, L.
    Radue, E. W.
    Cohen, J.
    Barkhof, F.
    Sprenger, T.
    Meier, D. Piani
    Haering, D.
    Tomic, D.
    De Stefano, N.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 61 - 61
  • [45] Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis
    Chard, DT
    Griffin, CM
    Rashid, W
    Davies, GR
    Altmann, DR
    Kapoor, R
    Barker, GJ
    Thompson, AJ
    Miller, DH
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (10): : 1456 - 1456
  • [46] Prevalence of whole and regional brain atrophy in newly diagnosed relapsing-remitting MS patients
    Rodriguez Murua, S.
    Chaves, H.
    Correale, J.
    Fernandez Slezak, D.
    Farez, M. F.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 791 - 792
  • [47] Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
    Rudick, RA
    Fisher, E
    Lee, JC
    Simon, J
    Jacobs, L
    NEUROLOGY, 1999, 53 (08) : 1698 - 1704
  • [48] Does fatigue in early relapsing-remitting multiple sclerosis correlate with brain atrophy?
    Ostermann, B
    Ecker, D
    Brettschneider, J
    Tumani, H
    Kassubek, J
    JOURNAL OF NEUROLOGY, 2004, 251 : 122 - 122
  • [49] Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis
    Chard, DT
    Griffin, CM
    Rashid, W
    Davies, GR
    Altmann, DR
    Kapoor, R
    Barker, GJ
    Thompson, AJ
    Miller, DH
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) : 387 - 391
  • [50] The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS
    Saindane, AM
    Ge, Y
    Udupa, JK
    Babb, JS
    Mannon, LJ
    Grossman, RI
    NEUROLOGY, 2000, 55 (01) : 61 - 65